Effects of antagonists at the human recombinant P2X₇ receptor

Abstract

1. We have used whole-cell patch clamping methods to examine the properties of the recombinant human P2X₇ (P2Z) receptor stably expressed in HEK-293 cells.

2. In an extracellular solution with lowered concentrations of divalent cations (zero Mg²⁺ and 0.5 mM Ca²⁺), both ATP and the nucleotide analogue, 2′- and 3′-O-(4-benzoylbenzoyl)-adenosine 5′-triphosphate (Bz-ATP) evoked concentration-dependent whole-cell inward currents with maxima of 4658±671 and 5385±990 pA, respectively, at a holding potential of −90 mV. Current-voltage relationships determined using 100 μM Bz-ATP reversed at −2.7±3.1 mV, and did not display significant rectification.

3. Repeated applications of 300 μM Bz-ATP produced inward currents with similar rise-times (approx. 450 ms, 5–95% current development) but with progressively slower 95–5% decay times, with the eighth application of this agonist yielding a decay time of 197% of the first application.

4. Concentration-effect curves to ATP and Bz-ATP produced estimated EC₅₀ values of 780 and 52.4 μM, respectively. Consecutive concentration-effect curves to Bz-ATP produced curves with similar maxima and EC₅₀ values.

5. The non-selective P2 antagonists, pyridoxal-phosphate-6-azophenyl-, 2′,4′-disulphonic acid (PPADS) and suramin, both produced concentration-dependent increases in maximal inward currents to Bz-ATP, with IC₅₀ concentrations of approximately 1 μM and 70 μM, respectively. The profile of antagonism produced by PPADS was not that of a competitive antagonist.

6. The isoquinolene derivatives 1-(N,O-bis[5-isoquinolinesulphonyl]-N-methyl-L-tyrosyl)-4-phenylpiperazine (KN-62) and calmidazolium both produced antagonism which was not competitive, with IC₅₀ concentrations of approximately 15 and 100 nM, respectively. HMA (5-(N,N-hexamethylene)- amiloride) was also an effective antagonist at a concentration of 10 μM. The group IIb metal, copper, also displayed antagonist properties at the human P2X₇ receptor, reducing the maximum response to Bz-ATP by about 50% at a concentration of 1 μM.

7. These data demonstrate that the human recombinant P2X₇ receptor displays functional behaviour which is similar to the recombinant rat P2X₇ receptor, but has a distinct pharmacological profile with respect to agonist and antagonist sensitivity.

Full Text

The Full Text of this article is available as a PDF (527.0 KB).